Sage Therapeutics, Inc. (SAGE)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 12.89 |
| Open | 12.91 |
| Bid | 12.90 x 300 |
| Ask | 12.97 x 200 |
| Day's range | 12.74 - 13.38 |
| 52-week range | 10.92 - 59.99 |
| Volume | |
| Avg. volume | 998,117 |
| Market cap | 778.382M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
- Zacks
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Investor's Business Daily
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
Sage Therapeutics said Wednesday its Parkinson's treatment failed in a midstage study, and Sage stock collapsed to a record low.
© 2024 Yahoo. All rights reserved.